Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

93 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An IL-2 mutein increases IL-10 and CTLA-4-dependent suppression of dendritic cells by regulatory T cells.
Jamison BL, Lawrance M, Wang CJ, DeBerg HA, Sansom DM, Gavin MA, Walker LSK, Campbell DJ. Jamison BL, et al. Among authors: sansom dm. bioRxiv [Preprint]. 2023 Dec 4:2023.12.01.569613. doi: 10.1101/2023.12.01.569613. bioRxiv. 2023. Update in: Cell Rep. 2024 Nov 26;43(11):114938. doi: 10.1016/j.celrep.2024.114938 PMID: 38106196 Free PMC article. Updated. Preprint.
Lack of phosphatidylinositol 3-kinase VPS34 in regulatory T cells leads to a fatal lymphoproliferative disorder without affecting their development.
Courreges CJF, Davenport ECM, Bilanges B, Rebollo-Gomez E, Hukelmann J, Schoenfelder P, Edgar JR, Sansom D, Scudamore CL, Roychoudhuri R, Garden OA, Vanhaesebroeck B, Okkenhaug K. Courreges CJF, et al. Front Immunol. 2024 Nov 27;15:1374621. doi: 10.3389/fimmu.2024.1374621. eCollection 2024. Front Immunol. 2024. PMID: 39664390 Free PMC article.
Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodies.
Lax BM, Palmeri JR, Lutz EA, Sheen A, Stinson JA, Duhamel L, Santollani L, Kennedy A, Rothschilds AM, Spranger S, Sansom DM, Wittrup KD. Lax BM, et al. Among authors: sansom dm. Proc Natl Acad Sci U S A. 2023 Aug;120(31):e2300895120. doi: 10.1073/pnas.2300895120. Epub 2023 Jul 24. Proc Natl Acad Sci U S A. 2023. PMID: 37487077 Free PMC article.
Therapeutic gene editing of T cells to correct CTLA-4 insufficiency.
Fox TA, Houghton BC, Petersone L, Waters E, Edner NM, McKenna A, Preham O, Hinze C, Williams C, de Albuquerque AS, Kennedy A, Pesenacker AM, Genovese P, Walker LSK, Burns SO, Sansom DM, Booth C, Morris EC. Fox TA, et al. Among authors: sansom dm. Sci Transl Med. 2022 Oct 26;14(668):eabn5811. doi: 10.1126/scitranslmed.abn5811. Epub 2022 Oct 26. Sci Transl Med. 2022. PMID: 36288278
Differences in CD80 and CD86 transendocytosis reveal CD86 as a key target for CTLA-4 immune regulation.
Kennedy A, Waters E, Rowshanravan B, Hinze C, Williams C, Janman D, Fox TA, Booth C, Pesenacker AM, Halliday N, Soskic B, Kaur S, Qureshi OS, Morris EC, Ikemizu S, Paluch C, Huo J, Davis SJ, Boucrot E, Walker LSK, Sansom DM. Kennedy A, et al. Among authors: sansom dm. Nat Immunol. 2022 Sep;23(9):1365-1378. doi: 10.1038/s41590-022-01289-w. Epub 2022 Aug 23. Nat Immunol. 2022. PMID: 35999394 Free PMC article.
93 results